In Treatment and prevention of Blood clots Nadropar 2850IU Injection prevents new blood clots from forming and prevents the existing ones from getting bigger. It works by blocking a substance in the body which is involved in blood clotting. Thus it helps your blood flow smoothly throughout the body. This can help reduce damage caused by clots in your lungs (pulmonary embolism), brain (stroke), heart (heart attack), or other blood vessels (thrombosis). It can also be used to prevent clots from forming after surgery, for example, to replace a knee or hip joint. Although it does not “dissolve” blood clots, it can prevent them from getting bigger so your body can dissolve them over time. It can also make it less likely that parts of a clot will break off and travel to other parts of the body.
It is not known whether it is safe to consume alcohol with Nadropar 2850IU Injection. Please consult your doctor.
Nadropar 2850IU Injection may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Nadropar 2850IU Injection is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
It is not known whether Nadropar 2850IU Injection alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Nadropar 2850IU Injection should be used with caution in patients with severe kidney disease. Dose adjustment of Nadropar 2850IU Injection may be needed. Please consult your doctor.
There is limited information available on the use of Nadropar 2850IU Injection in patients with liver disease. Please consult your doctor.
If you miss a dose of Nadropar 2850IU Injection, please consult your doctor.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More
Marketer/Manufacturer: Glaxo SmithKline Pharmaceuticals Ltd || ₹14.5/tablet (25% cheaper)